

Sandro Mazzaferro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8651185/publications.pdf>

Version: 2024-02-01

118
papers

2,908
citations

147801

31
h-index

197818

49
g-index

119
all docs

119
docs citations

119
times ranked

3176
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of the implementation of a triage system of vascular access performance in haemodialysis patients: experience of a single dialysis centre. <i>Journal of Nephrology</i> , 2022, 35, 969-976.	2.0	2
2	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. <i>Nutrients</i> , 2022, 14, 1742.	4.1	8
3	MO792: Validation and Applicability of an Innovative Monitoring System for Vascular Access in Haemodialysis—A Multicentre Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
4	MO545: Estimated Proximal Tubule Fluid Phosphate Concentration: An Early Marker of CKD-MBD?. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
5	Diastolic Pressure and ACR Are Modifiable Risk Factors of Arterial Stiffness in T2DM Without Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3857-e3865.	3.6	1
6	Dialysate calcium concentration during calcimimetic treatment: a neglected issue. <i>Journal of Nephrology</i> , 2021, 34, 19-22.	2.0	1
7	Bone biopsy in chronic kidney disease: still neglected and in need of revitalization. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 202-204.	0.7	5
8	European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 42-59.	0.7	107
9	Renal resistive index in IgA nephropathy and renal scleroderma vasculopathy. <i>Microvascular Research</i> , 2021, 133, 104095.	2.5	4
10	Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. <i>Calcified Tissue International</i> , 2021, 108, 452-460.	3.1	17
11	Oxygen extraction ratio to identify patients at increased risk of intradialytic hypotension. <i>Scientific Reports</i> , 2021, 11, 4801.	3.3	2
12	Waves of infection and waves of communication: the importance of sharing in the era of Covid-19. <i>Journal of Nephrology</i> , 2021, 34, 633-636.	2.0	2
13	Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression. <i>Journal of Clinical Medicine</i> , 2021, 10, 958.	2.4	9
14	Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment. <i>Life</i> , 2021, 11, 419.	2.4	38
15	MO959KIDNEY TRANSPLANT TRANSITION FROM PEDIATRIC TO ADULT FACILITY CARE: DIFFICULTIES AND RISK FACTORS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
16	MO420ROLE OF IL-6 ON ACUTE KIDNEY INJURY (AKI) DEVELOPMENT AFTER LIVER TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
17	A simple visual clot scoring system allows reduction of the dose of low molecular weight heparin in hemodialysis. <i>Hemodialysis International</i> , 2021, 25, 560-562.	0.9	0
18	The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism. <i>Nutrients</i> , 2021, 13, 2328.	4.1	11

#	ARTICLE	IF	CITATIONS
19	Ischemic Nephropaty: The Role of the Renal Artery Stenosis Revascularization on Renal Stem Cells. <i>Medicina (Lithuania)</i> , 2021, 57, 944.	2.0	3
20	Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study. <i>Current Vascular Pharmacology</i> , 2021, 19, 556-564.	1.7	4
21	Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease. <i>Life</i> , 2021, 11, 1200.	2.4	7
22	A new technique for measuring fistula flow using venous blood gas oxygen saturation in patients with a central venous catheter. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 184-187.	2.9	2
23	Valvular heart disease and calcification in CKD: more common than appreciated. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2046-2053.	0.7	62
24	Î±-lipoic acid in patients with autosomal dominant polycystic kidney disease. <i>Nutrition</i> , 2020, 71, 110594.	2.4	12
25	On the role of skin biopsy in the diagnosis of calcific uremic arteriolopathy: a case-based discussion. <i>Journal of Nephrology</i> , 2020, 33, 859-865.	2.0	7
26	Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status. <i>Journal of Nutrition and Metabolism</i> , 2020, 2020, 1-8.	1.8	1
27	Association between Multidimensional Prognostic Index and Hospitalization and Mortality among Older Adults with Chronic Kidney Disease on Conservative or on Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3965.	2.4	7
28	Prebiotic Therapy with Inulin Associated with Low Protein Diet in Chronic Kidney Disease Patients: Evaluation of Nutritional, Cardiovascular and Psychocognitive Parameters. <i>Toxins</i> , 2020, 12, 381.	3.4	11
29	Bone, inflammation and chronic kidney disease. <i>Clinica Chimica Acta</i> , 2020, 506, 236-240.	1.1	26
30	Parathyroidectomy in Chronic Kidney Disease. , 2020, , 175-185.		0
31	Calciphylaxis: a conundrum for patients and nephrologists?. <i>Journal of Nephrology</i> , 2019, 32, 677-680.	2.0	2
32	Direct bone effects of calcimimetics in chronic kidney disease?. <i>Kidney International</i> , 2019, 95, 1012-1014.	5.2	4
33	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	1.9	17
34	Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis. <i>Journal of Translational Medicine</i> , 2019, 17, 388.	4.4	19
35	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
36	Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy. <i>Nutrition</i> , 2019, 62, 108-114.	2.4	56

#	ARTICLE	IF	CITATIONS
37	Clinical impact of vitamin D hydroxylation efficiency. <i>Minerva Medica</i> , 2019, 110, 259-262.	0.9	4
38	Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. <i>Calcified Tissue International</i> , 2018, 103, 111-124.	3.1	45
39	Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2092-2100.	0.7	26
40	Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. <i>Endocrine</i> , 2018, 59, 242-259.	2.3	15
41	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 319-331.	11.4	102
42	Multicenter study on parathyroidectomy (PTX) in Italy: preliminary results. <i>Journal of Nephrology</i> , 2018, 31, 767-773.	2.0	5
43	Obesity and kidney stone disease: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 393-400.	3.9	69
44	Oxygen Extraction Ratio (OER) as a Measurement of Hemodialysis (HD) Induced Tissue Hypoxia: A Pilot Study. <i>Scientific Reports</i> , 2018, 8, 5655.	3.3	7
45	Renal Diseases and Skeletal Health. , 2018, , 183-209.		0
46	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1608-1613.	0.7	41
47	Positioning novel biologicals in CKD-mineral and bone disorders. <i>Journal of Nephrology</i> , 2017, 30, 689-699.	2.0	11
48	The Risk of Chronic Kidney Disease Associated with Urolithiasis and its Urological Treatments: A Review. <i>Journal of Urology</i> , 2017, 198, 268-273.	0.4	78
49	Fibroblast Growth Factor 23: Mineral Metabolism and Beyond. <i>Contributions To Nephrology</i> , 2017, 190, 83-95.	1.1	30
50	Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 686-701.	7.3	84
51	Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?. <i>Journal of Nephrology</i> , 2017, 30, 621-622.	2.0	3
52	Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. <i>PLoS ONE</i> , 2017, 12, e0178637.	2.5	22
53	A new Hyperphosphatemia Drug. <i>Giornale De Tecniche Nefrologiche & Dialitiche</i> , 2016, 28, 12-15.	0.1	0
54	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , 2016, 29, 126-140.	0.5	18

#	ARTICLE	IF	CITATIONS
55	Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1269-1280.	4.5	17
56	Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology. Journal of Nephrology, 2016, 29, 305-328.	2.0	26
57	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
58	Vitamin D: a dynamic molecule. How relevant might the dynamism for a vitamin be?. Nephrology Dialysis Transplantation, 2016, 31, 23-30.	0.7	25
59	Interaction Between Vitamin D and Calcimimetics in Chronic Kidney Disease. , 2016, , 537-562.		1
60	Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?. BBA Clinical, 2015, 3, 251-256.	4.1	33
61	Soluble Klotho Serum Levels in Chronic Kidney Disease. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	67
62	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). CKJ: Clinical Kidney Journal, 2015, 8, 567-571.	2.9	12
63	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
64	Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. BMC Nephrology, 2015, 16, 11.	1.8	12
65	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
66	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
67	Vascular calcification, bone and mineral metabolism after kidney transplantation. World Journal of Transplantation, 2015, 5, 222.	1.6	14
68	Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. International Journal of Nephrology and Renovascular Disease, 2014, 8, 1.	1.8	3
69	Editorial (Thematic issue :VITAMIN D THERAPY: AN UPDATE Available Experimental and Clinical Evidences) Tj ETQq1 1 0.784314 rgBT 12, 271-271.	1.7	0
70	News on Biomarkers in CKD-MBD. Seminars in Nephrology, 2014, 34, 598-611.	1.6	44
71	When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 612-625.	1.6	53
72	Calcific Uremic Arteriopathy: A Call for Action. Seminars in Nephrology, 2014, 34, 641-647.	1.6	21

#	ARTICLE	IF	CITATIONS
73	Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort. <i>Blood Purification</i> , 2014, 38, 37-45.	1.8	20
74	Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. <i>Journal of Nephrology</i> , 2014, 27, 483-494.	2.0	6
75	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1815-1820.	0.7	103
76	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 427-436.	11.4	125
77	Vitamin D Metabolites and/or Analogs; Which D for Which Patient?. <i>Current Vascular Pharmacology</i> , 2014, 12, 339-349.	1.7	50
78	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 984-992.	1.9	34
79	Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1672-1679.	0.7	118
80	VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3588-3594.	0.7	52
81	Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. <i>Journal of Medical Economics</i> , 2012, 15, 1110-1117.	2.1	7
82	Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23. <i>Journal of Nephrology</i> , 2012, 25, 1108-1118.	2.0	16
83	Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality. <i>Blood Purification</i> , 2011, 32, 124-132.	1.8	30
84	The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 402-407.	0.7	33
85	Treatment of Cardiovascular Calcification in Uremia. <i>Current Vascular Pharmacology</i> , 2011, 9, 741-749.	1.7	6
86	Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. <i>Journal of Nephrology</i> , 2011, 24, 225-235.	2.0	15
87	New insights into the role of calcium-sensing receptor activation. <i>Journal of Nephrology</i> , 2011, 24, 38-41.	2.0	4
88	The bone and the kidney. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 95-102.	3.0	29
89	The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease. <i>Current Vascular Pharmacology</i> , 2010, 8, 404-411.	1.7	31
90	Vitamin D Receptor Activators. <i>International Journal of Artificial Organs</i> , 2009, 32, 101-107.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Progression of Coronary Artery Calcification in Renal Transplantation and the Role of Secondary Hyperparathyroidism and Inflammation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 685-690.	4.5	82
92	Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2859-2865.	0.7	14
93	Vascular Calcification and Uremia: What Do We Know?. <i>American Journal of Nephrology</i> , 2008, 28, 339-346.	3.1	72
94	Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQITM ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2319-2323.	0.7	40
95	Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison between Transplantation and Dialysis. <i>American Journal of Nephrology</i> , 2007, 27, 75-83.	3.1	51
96	Morphometric X-ray absorptiometry in the assessment of vertebral fractures in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 466-471.	0.7	33
97	How Can We Assess Bone Resorption in Uremia?. <i>Nephron Clinical Practice</i> , 2004, 98, c103-c104.	2.3	1
98	Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone. <i>Osteoporosis International</i> , 2002, 13, 171-175.	3.1	44
99	Ionised and total serum magnesium in renal transplant patients. <i>Journal of Nephrology</i> , 2002, 15, 275-80.	2.0	6
100	Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. <i>Histopathology</i> , 2001, 38, 571-583.	2.9	27
101	Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 877-882.	0.7	28
102	Prospective Evaluation of Total Parathyroidectomy and Autotransplantation for the Treatment of Secondary Hyperparathyroidism. <i>Archives of Surgery</i> , 1999, 134, 68.	2.2	25
103	Changes in adrenomedullin plasma concentrations during haemodialysis in patients with chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 519-520.	0.7	5
104	Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2294-2302.	0.7	120
105	Effects of Haemodialysis Session on Plasma Beta-Endorphin, ACTH and Cortisol in Patients with End-Stage Renal Disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 1996, 30, 399-402.	1.4	23
106	Safe Employment of Recombinant Human Erythropoietin in Pregnancy in Two Anuric Patients on Regular Dialysis Treatment. <i>Renal Failure</i> , 1995, 17, 73-76.	2.1	1
107	Extent of alkaline phosphatase cytochemistry vs. extent of tetracycline fluorescence in the evaluation of histodynamic variables of bone formation. <i>Bone</i> , 1995, 16, 493-498.	2.9	5
108	Bone Metabolism and Its Assessment in Renal Failure. <i>Nephron</i> , 1994, 67, 383-401.	1.8	27

#	ARTICLE	IF	CITATIONS
109	Procollagen Type 1 C-Terminal Extension Peptide Serum Levels following Parathyroidectomy in Hyperparathyroid Patients. <i>American Journal of Nephrology</i> , 1994, 14, 106-112.	3.1	21
110	Evaluation of osteoblastic activity by morphometric comparison of alkaline phosphatase cytochemistry vs. tetracycline fluorescence. <i>Bone</i> , 1993, 14, 321-326.	2.9	5
111	Procollagen type 1 C-terminal extension peptide, PTH and 1,25(OH)2D3 in chronic renal failure. <i>Bone</i> , 1993, 14, 415-420.	2.9	9
112	Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 42, 823-829.	2.5	1
113	Calcium density measurement in histological samples of trabecular bone of normal subjects: Relationship with aging. <i>Archives of Gerontology and Geriatrics</i> , 1992, 15, 27-35.	3.0	0
114	Procollagen Type I C-Terminal Extension Peptide in Predialysis Chronic Renal Failure. <i>American Journal of Nephrology</i> , 1992, 12, 246-251.	3.1	39
115	Autonomic neuropathy and secondary hyperparathyroidism in uremia. <i>Journal of the Autonomic Nervous System</i> , 1990, 30, S149-S151.	1.9	2
116	PIXE technique for calcium analysis of human bone. <i>Biological Trace Element Research</i> , 1986, 10, 123-127.	3.5	2
117	Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. <i>Kidney International</i> , 1985, 28, 783-790.	5.2	39
118	Circannual versus seasonal variations of longitudinally sampled 25-hydroxycholecalciferol serum levels. <i>Biochemical Medicine</i> , 1984, 32, 22-29.	0.5	4